Abstract
In the first article of this series, we presented some evidence of hyperforin as an antibiotic, antiprotozoal, antiviral, anticancer, and immunomodulatory substance. In the present article, evidence of the permeability of the blood-testis barrier (BTB) and blood-brain barrier (BBB) to hyperforin and its distribution in other organs of the domestic pig (Sus scrofa domesticus) are revealed. Seven-month-old male boars with a body mass of 100 kg were fed a diet containing hyperforin. Organs were surgically removed under anesthesia. Organs were suitable prepared and extracted, and then analyzed using gas chromatography-mass spectrometry with supersonic molecular beams (GC-MS with SMB). The presence of hyperforin was recorded in all organs and body fluids. Special attention was paid to the evaluation of the presence of hyperforin in the brain and testes of experimental animals. The presence of hyperforin in the brain and testes of experimental animals was established by GC-MS with SMB. The results are of interest because penicillin and numerous other antibiotics cannot pass through the BTB or BBB if healthy or non-inflamed, which limits their use in patients with meningitis and gonorrhea. The findings are also of interest in cases of penicillin- and multi-antibiotic-resistant bacterial infections.
Highlights
A previous publication [1] has explained the urgent necessity for the development and introduction of a new generation of antibiotics with the ability to act against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant microorganisms, as well as against multi-antibiotic-resistant bacteria, into medical practice
In the first article of this series, we presented some evidence of hyperforin as an antibiotic, antiprotozoal, antiviral, anticancer, and immunomodulatory substance
The results are of interest because penicillin and numerous other antibiotics cannot pass through the blood-testis barrier (BTB) or blood-brain barrier (BBB) if healthy or non-inflamed, which limits their use in patients with meningitis and gonorrhea
Summary
A previous publication [1] has explained the urgent necessity for the development and introduction of a new generation of antibiotics with the ability to act against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant microorganisms, as well as against multi-antibiotic-resistant bacteria, into medical practice. Previous research [2] described some microorganisms affected by hyperforin, including those that are penicillin-resistant. After Brondz completed a graduate degree in the pharmaceutical sciences in 1979, he performed all research on the medical use of hyperforin at a private company, Jupiter, and later at Jupiter AS (Jupiter Ltd.) because of the unscientific, unethical approach of Docent Aasen (Pharmaceutical Department, University of Oslo, Norway), who aimed to commercialize the scientific work of Brondz without his knowledge
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Analytical Mass Spectrometry and Chromatography
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
